Article: INDIA'S NATCO RECALLS BREAST CANCER DRUG 'ALBUPAX'.

NEW DELHI, July 20 Asia Pulse - Indian drug firm Natco Pharma (BSE:524816) on Saturday said it has stopped the production and marketing of breast cancer drug 'Albupax', after tests showed that it might cause damage to the liver.

The Indian Health Regulator Drug Controller General of India (DCGI) DCGI has sent a letter to the company asking them to stop the production, distribution and marketing of the drug, according to sources.

"As per DCGI office, we have stopped marketing the product in the interim," Natco Pharma said in an e-mail response.

When asked about it, the company ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!